消融前甲状腺球蛋白抗体阳性与儿童甲状腺乳头状癌患者结局无关联
这项多中心回顾性研究纳入2005—2020年中国西南3家三级医院收治的132例18岁及以下甲状腺乳头状癌患者,比较消融前甲状腺球蛋白抗体(TgAb)阳性与阴性者的肿瘤特征和长期结局。结果显示两组肿瘤特征、淋巴结转移及随访时间相似,因淋巴结转移再次手术、重复131I治疗及最终随访时结构性病变比例均无显著差异。
要点
- 消融前TgAb阳性率为37.1%,两组肿瘤特征与淋巴结转移相似。
- TgAb阳性组 vs TgAb阴性组因淋巴结转移再次手术比例为4.1% vs 4.8%(P=1.000)。
- 最终随访时两组结构性病变比例分别为6.1% vs 4.8%(P=0.710),无显著差异。
核心结论
- 该多中心研究显示,儿童甲状腺乳头状癌患者消融前TgAb阳性与临床结局无关联。
研究设计与样本
- 多中心回顾性研究,纳入2005—2020年中国西南3家三级医院连续收治的18岁及以下、接受全甲状腺切除和放射性碘消融的甲状腺乳头状癌患者。
- 消融前检测甲状腺球蛋白抗体,比较TgAb阳性与TgAb阴性患者的肿瘤特征和长期结局,共分析132例患者。
主要发现
- 消融前TgAb阳性见于37.1%的患者。
- TgAb阳性与TgAb阴性患者的肿瘤特征、淋巴结转移及中位随访时间相似。
- 随访期间因淋巴结转移再次手术的比例为TgAb阳性组4.1% vs TgAb阴性组4.8%(P=1.000),两组相似。
- 重复131I治疗的比例为TgAb阳性组14.3% vs TgAb阴性组20.5%(P=0.373),两组相似。
- 最终随访时结构性病变比例为TgAb阳性组6.1% vs TgAb阴性组4.8%(P=0.710),两组无差异。
关键数值与推荐
- 消融前TgAb阳性率37.1%。
- 因淋巴结转移再次手术:TgAb阳性组4.1% vs TgAb阴性组4.8%,P=1.000。
- 重复131I治疗:TgAb阳性组14.3% vs TgAb阴性组20.5%,P=0.373。
- 最终随访结构性病变:TgAb阳性组6.1% vs TgAb阴性组4.8%,P=0.710。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This multicenter study was designed to evaluate the relationship between preablation thyroglobulin antibody (TgAb) positivity and clinical outcomes in pediatric patients with papillary thyroid carcinoma (PTC). METHODS: In the period 2005-2020, all consecutive PTC patients 18 years or younger who underwent total thyroidectomy and radioiodine ablation at 3 tertiary hospitals in southwestern China were retrospectively included. Thyroglobulin antibody was measured before remnant ablation. Tumor characteristics and long-term outcomes were compared between TgAb-positive and TgAb-negative patients. RESULTS: One hundred thirty-two patients were analyzed. Preablation TgAb positivity was presented in 37.1% of patients. Tumor characteristics, lymph node metastases, and median duration of follow-up were similar between TgAb-positive and -negative patients. During follow-up, the percentage of patients with either surgical reintervention for lymph node metastases (4.1% vs 4.8%, P = 1.000) or repeated 131 I therapy (14.3% vs 20.5%, P = 0.373) was similar between TgAb-positive and -negative patients. At the final follow-up visit, the rates of structural disease did not differ between the 2 groups (6.1% vs 4.8%, P = 0.710). CONCLUSIONS: This multicentric study highlights no association of preablation TgAb positivity and clinical outcome in pediatric patients with PTC.
引用
- Xu Y, Shi L, Wu J, et al. No Association of Preablation Thyroglobulin Antibody Positivity and Outcome in Pediatric Patients With Papillary Thyroid Carcinoma. Clin Nucl Med. 2023. PMID: 37385237. doi:10.1097/RLU.0000000000004758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。